Photo taken from Pashtoon Kasi/Twitter
Sep 21, 2023, 11:16
Pashtoon Kasi: Are we on the verge of a new drug combo for colorectal cancer?
Pashtoon Kasi, the Director of Colon Cancer Research at Weill Cornell Medicine, shared on X/Twitter:
“Forbes Published today!
Are we on the verge of a new drug combo for colorectal cancer?
Read more about our work on this immunotherapy called the BOT (Botensilimab).
We describe this “inside-out” wave of regression by immune cells.
Here’s the full text to the article in Oncogene Journal, Nature.
Herein, we describe the “inside-out” (serosa-to-mucosa) pattern of response seen with neoadjuvant BOT alongside BAL in patients with pMMR/MSS colon and rectal cancer.
brief animation summarizing the immune REGRESSION. regression /rɪˈɡrɛʃn,ˌriːˈɡrɛʃn/- noun.
1. a return to a former or less developed state.
This is the kind of “mop-up” we are seeing.
We enrolled 12 at a rapid pace & completed within ~3 months. The study already now expanding to 2 additional cohorts to study dosing, timing and/or need for surgery. Cohort A results to be unveiled at an upcoming meeting.
Pattern of regression is intriguing.
Here are the detailed results for Open Access.
“Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer.”
NEST-01 Clinical Trial. ”
For details click here.
Source: Pashtoon Kasi/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 15:20
Nov 14, 2024, 14:40
Nov 14, 2024, 14:39
Nov 14, 2024, 14:28
Nov 14, 2024, 14:05